MULTIPLE MYELOMA: CHALLENGES OF DIFFERENTIAL DIAGNOSIS (CLINICAL CASE)-Reference-Cited by-同舟云学术

MULTIPLE MYELOMA: CHALLENGES OF DIFFERENTIAL DIAGNOSIS (CLINICAL CASE)

Published:2020-01 Issue:1 Volume:73 Page:203-207
ISSN:0043-5147
Container-title:Wiadomości Lekarskie
language:en
Short-container-title:Wiad Lek

Author:

Baranova Iryna V.¹,Postovitenko Kateryna P.²,Iliuk Iryna A.³,Kolisnyk Sergii P.²,Gumeniuk Alla F.⁴,Katiukha Vitalii L.⁵,Dolynna Olena V.²,Kurylenko Iryna V.⁶

Affiliation:

1. DEPARTMENT OF MEDICAL REHABILITATION AND MEDICAL-SOCIAL EXPERTISE, NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE; UNIVERSITY CLINIC NPMMU, REHABILITATION DEPARTMENT, VINNYTSIA, UKRAINE

2. DEPARTMENT OF MEDICAL REHABILITATION AND MEDICAL-SOCIAL EXPERTISE, NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE

3. DEPARTMENT OF INTERNAL MEDICINE №2, NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE

4. DEPARTMENT OF INTERNAL MEDICINE MEDICAL FACULTY №2, NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE

5. CITY CLINICAL HOSPITAL, POLICLINIC DEPARTMENT, VINNYTSIA, UKRAINE

6. SCIENTIFIC AND RESEARCH INSTITUTE OF INVALID REHABILITATION OF NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE

Abstract

The objective of our study was to interpret and discuss atypical multiple myeloma case. The article describes the case of clinical observation of a patient K, in which manifestations of chronic kidney disease and circulatory failure prevailed in clinical picture of the disease. The authors recommended an X-ray examination of skull and pelvic bones as a screening method suitable for elderly people with symptoms of chronic renal insufficiency and chronic bone and muscle pain resistant to treatment.

Publisher

ALUNA

Subject

General Medicine

Reference27 articles.

1. 1. Landgren O, Rajkumar Vincent S. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clinical Cancer Research 2016; 22(22): 5428-5433. doi: 10.1158/1078-0432. CCR-16-0866.

2. 2. Kumar S, Paiva B, Anderson K et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology 2016; 17(8): e328-e346, doi: 10.1016/S1470-2045(16)30206-6.

3. 3. Orlowski R, Lonial S. Integration of novel agents into the care of patients with multiple myeloma. Clinical Cancer Research 2016; 22(22): 5443- 5452, doi: 10.1158/1078-0432.CCR-16-0861.

4. 4. Livandovskii UA, Rybina OB. Multiple myeloma with monoclonal immunoglobulin A exhibiting and hypercholesterolemia: case report and literature review. Kardiosomatika 2015; 1(1): 50-52 (in Russian).

5. 5. Dingli D, Ailawadhi S, Bergsagel Leif P et al. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clinic Proceedings [serial online] 2017 Feb [cited 15.09.2017]. Available from URL: http://www. mayoclinicproceedings.org.